Clinical Trial Update: Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform [Phase 1]

View source ↗

Summary

Phase 1 open-label trial to evaluate the safety of combining Afatinib with radiotherapy, with or without temozolomide, in newly diagnosed glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Afatinib (afatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Glioblastoma | Phase 1 | Status: COMPLETED | Results posted: 2019-02-18